PETV - Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

John Dolan

Greetings, everyone. And welcome to the PetVivo Holdings First Quarter of Fiscal 2023 Financial Results Conference Call. I am John Dolan, the Chief Business Development Officer and General Counsel at PetVivo. Today's call is being webcast and will be posted on the company's website for playback.

Before we begin, I would like to remind everyone that comments made during this conference call by PetVivo executives may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks and uncertainties. to financial or conditions projections, forward-looking refers future characterizations is that statement. including events, or statement expectations, other projections of a Any future market such materially future listed those SEC those could actual its for differ PetVivo’s expressed reason, results in and forward-looking filings. including statements any from statements. assumes PetVivo forward-looking obligation update to no such any PetVivo filed provides Form detailed of discussion and a results. the with its XX-Q earnings our release which SEC financial today, website. be can Relations in the and website Investor our found SEC section the of These documents I the of Lai, would turn the CEO John like over to to conference and PetVivo. President ahead, go John. Please

John Lai

Thank you, John, and welcome.

continue our Joining Financial last me thoughts today by our financial is the XXXX well will strategy Robert as before discussing discuss for will of some I Folkes, up from begin like the some results line key the Folkes business for I focus for additional highlights Chief to as and in sharing questions. would we detail. areas condition fiscal Bob then quarter, Officer. financial our greater open

Our subsidiary entered MWI, into animal leading products. key distribution of fiscal XXXX, symbol with exclusive agreement first we the distributor and sales AmerisourceBergen, which highlights is a ticker health ABC, a of of quarter for

now we're financial to the accounts will our recently states, have also Chief Officer, over our coverage Financial and the pretty map completed offering condition. -- who to discuss XX We call that's getting area. so turn I in registered like in good would Robert Folkes,

Robert Folkes

our fiscal our in we've as working -- support also had studies Spryng. with marketing increased these from of good from And expected PetVivo We and and -- to order mentioned, efforts, the and million acceptance $X.X John, expand you, At XXX,XXX awareness and and accounts, and John continue opening opened sale off XXXX growth XX, has revenues sales in paying clinical increase our net our to proceeds inventory the thank of the everyone. public capital to to our marketing sales initial offering marketing our sales -- our revenue use $X.X and Well, we and ‘XX. June been to XXXX, in investment in cash afternoon, company gain the million.

now so to call the John. will back And turn I

John Lai

exhibiting would Bob. and our both areas talked requirement. some sales also creating territorial veterinary And hiring the like to We're we're small relationship about conferences will of about of be multiple animals our market, from major business and these is fiscal I clinical speaking and to support be and managers more at additional equine not animal for and talk influencers have the multiple conventions. strategy XXXX. marketing you, for key we the small going to more at support generating focus evidence this that to and -- and Thank studies MWI, have equine with space We forSpryng. also regulatory awareness

like take Now, open would you questions. explain up it for can to process? over I and the Operator, please

Operator

allow There is already to you their someone raised. go. [Operator them to Instructions] going I'm There talk. hand with

talk be the email, should gzplumtree@gmail. able to It's You now.

John Lai

maybe one. Operator, another then to go back you. come we one, believe Hello. that Gary, should that's I to and

Operator

It so at unmuted, talk. can any see other if this Okay. looks then I And hands like let us time. you're know don't you raised

John Lai

seconds, more We'll give then. him else a no few because there's one

Robert Folkes

unmuted. He's

John Lai

Yeah, it looks he’s like unmuted.

case? the repeat you calling for to process in want Lily, So people in, just

Operator

We The number can Instructions] one you in dialed who XXXX, talk. more in. question have ending [Operator do now

Gary Zwetchkenbaum

hear can me? Hello. John, you

John Lai

Yes, I can.

Gary Zwetchkenbaum

made completed, data are clinical and Great. these us? studies be there when are might in. Gary that studies several available It an important you understanding will calling my the give us Can when progress. is update in to that Zwetchkenbaum on be

John Lai

the to the you smaller equine said working for vets. can John, speeding well been studies. Yes. it will with as this John up our I on have be would can vets studies we much of John, over? these turn Pretty all [indiscernible] Dolan, of adoption is the has catalyst as along, animal over? Counsel take He General person. you Development who take it

John Dolan

to And to have mute number forward John continue go. that months. clinical only been for be a we seriously our are an the will XX want progress, implemented their and in distributors. is maybe We not have well and of next company. that incredibly for already initiative for to we're And customers, caller in started number them and going can. phone. I might or This already we the large as our to us actually, plan for and data studies as correct, There an that very of also our XX do planning is them we thing ongoing take a but

we've Now, now that studies right progress in talk two I can got are that about.

osteoarthritis. that also. be elbows that QX of in completed animal duration a one will up study that is be where a the This XXXX. in the small is This course, Of Colorado University. to is study want evaluate space. product basically injection test study very This of We're study -- Duerr. the is name a investigator we basically of veterinarian His on study -- will State have the animals Felix in the because intra-articular the is of well renowned set to principal anticipating is our product long we're hoping

results QX in data that released to sometime we public. of should those that the the QX So be and accumulated by will anticipating be XXXX anticipate we're

United is the for in Chand what now Ethos have That private right Spryng injections in is is, entity. States well-known also such stifle Veterinary with respected study by studies. institution study well-known on actually, with study We of a the a very disease. test to veterinarian -- an intra-articular going that Association. owned that's And National a is who's Khanna, performing dogs investigator primary the the

that And that's in study. -- a will the date completion QX actually the have of this though phase that expect study anticipate We of first so we it yet XXXX. to year

end done well The second as that will hopefully we'll before the year, publication in QX so of the data sometime this have reports on by phase year. we next and anticipate as of be

John Lai

not dates, fiscal dates? our calendar are those And

John Dolan

John. Correct. That is correct,

John Lai

questions, operator? other Any

Operator

No other hand time. at raised this

John Lai

I Okay. the and on dogs, as focused for conclude Spryng help with remain thanks in the everyone we operator, getting We can osteoarthritis. PetVivo. would horses market call. you, into Thank Then interest

also us to you. work great We today. in Again, our Thank OA continue to this develop you felines. other joining for call products product for included thank on

PetVivo (PETV) 13 Aug 222023 Q1 Earnings call transcript